Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition

Signal Transduct Target Ther. 2024 Sep 23;9(1):250. doi: 10.1038/s41392-024-01968-0.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Female
  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / genetics
  • Humans
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Janus Kinase Inhibitors / therapeutic use
  • Male

Substances

  • Immune Checkpoint Inhibitors
  • Janus Kinase Inhibitors